We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 28, 2020

Evolocumab Reduces Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy

JAMA Cardiology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Cardiology
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
JAMA Cardiol 2020 Aug 12;[EPub Ahead of Print], P Deedwania, SA Murphy, A Scheen, J Badariene, AL Pineda, N Honarpour, AC Keech, PS Sever, TR Pedersen, MS Sabatine, RP Giugliano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading